1014 related articles for article (PubMed ID: 15501986)
1. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
[TBL] [Abstract][Full Text] [Related]
2. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
[TBL] [Abstract][Full Text] [Related]
3. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
4. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
5. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
6. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
7. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.
Jeffrey SC; Andreyka JB; Bernhardt SX; Kissler KM; Kline T; Lenox JS; Moser RF; Nguyen MT; Okeley NM; Stone IJ; Zhang X; Senter PD
Bioconjug Chem; 2006; 17(3):831-40. PubMed ID: 16704224
[TBL] [Abstract][Full Text] [Related]
8. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
9. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
[TBL] [Abstract][Full Text] [Related]
10. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
[TBL] [Abstract][Full Text] [Related]
12. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
14. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
15. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
16. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.
Okeley NM; Miyamoto JB; Zhang X; Sanderson RJ; Benjamin DR; Sievers EL; Senter PD; Alley SC
Clin Cancer Res; 2010 Feb; 16(3):888-97. PubMed ID: 20086002
[TBL] [Abstract][Full Text] [Related]
17. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
Takahashi H; Adachi K; Yamaguchi F; Teramoto A
Anticancer Res; 1999; 19(5B):4151-5. PubMed ID: 10628367
[TBL] [Abstract][Full Text] [Related]
18. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
19. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.
Junutula JR; Raab H; Clark S; Bhakta S; Leipold DD; Weir S; Chen Y; Simpson M; Tsai SP; Dennis MS; Lu Y; Meng YG; Ng C; Yang J; Lee CC; Duenas E; Gorrell J; Katta V; Kim A; McDorman K; Flagella K; Venook R; Ross S; Spencer SD; Lee Wong W; Lowman HB; Vandlen R; Sliwkowski MX; Scheller RH; Polakis P; Mallet W
Nat Biotechnol; 2008 Aug; 26(8):925-32. PubMed ID: 18641636
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
Braslawsky GR; Edson MA; Pearce W; Kaneko T; Greenfield RS
Cancer Res; 1990 Oct; 50(20):6608-14. PubMed ID: 2208123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
